7 Top Penny Stocks That Investors Are Watching in July 2021
Creating a penny stocks watchlist is one of the most crucial steps to investing in small caps. While many choose to find penny stocks on Reddit or other social media sites, using research and information to create a watchlist will always be your best friend. Considering that there are hundreds of penny stocks to buy right now, picking only a handful can seem like a daunting task.
However, if you understand what type of investor you are, you can use that strategy to your advantage. In 2021, quite a few factors are impacting the stock market. However, the overarching theme remains the pandemic. Because of this, investors need to think one step ahead and consider how things will affect stocks in both the short and long term.
5 Hot Penny Stocks that Investors Are Watching Right Now
- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
- NexGen Energy Ltd. (NYSE: NXE)
- NovaBay Pharmaceuticals Inc. (NYSE: NBY)
- 9F Inc. (NASDAQ: JFU)
- Arbutus Biopharma Corp. (NASDAQ: ABUS)
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP)
Corbus Pharmaceuticals Holdings Inc. is a biotech penny stock that develops and commercializes novel therapeutics. These therapeutics target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead candidate is lenabasum, which is a cannabinoid receptor type 2 in a Phase III clinical trial to treat dermatomyositis, and a Phase II trial to treat systemic lupus erythematosus. On June 24th, Corbus announced topline results from its DETERMINE Phase III study of Lenabasum to treat dermatomyositis.
“We are disappointed that the trial did not meet the primary endpoint of TIS at Week 28. Nonetheless, we are encouraged by the results when the outcome is matched to the subtype of dermatomyositis in the study.
We believe we see clinical activity of lenabasum 20 mg administered twice daily compared to the control group just receiving standard background treatments, with higher TIS scores in classic dermatomyositis subjects with muscle weakness and skin involvement and greater reduction in CDASI activity score in subjects with active skin disease but normal muscle strength.”The Chief Medical Officer of CRBP, Barbara White M.D.
With biotech penny stocks heavily in focus right now, CRBP remains an interesting company to keep an eye on. With this recent trial in mind, and CRBP going up in price, will you add this penny stock to your watchlist?
NexGen Energy Ltd. (NYSE: NXE)
NexGen Energy Ltd. is an exploration and development stage mining penny stock that acquires, explores, and evaluates properties. These properties are generally involved in the uranium sector. Its principal asset is the Rook I project which consists of 32 contiguous mineral claims that total 35,065 hectares. This project is located in the Athabasca Basin, Saskatchewan. On June 24th the company announced its listing on the Australian Securities Exchange. This occurred on July 2nd, 2021 under the ticker NXG.
“NexGen has grown a substantial investor following in Australia and the Asia Pacific region since its founding in 2011. At present, approximately 30% of NexGen’s outstanding share capital is held by investors in the region.
Given the stage of the Company’s development, the exceptional economic strength of the Rook I Project, and the accelerating demand for the responsible production of clean energy worldwide, it is time to broaden the exposure of NexGen through a dual listing onto the ASX.”The CEO of NexGen Energy
NXE stock has increased substantially in the last 5 days. Only a week or so ago, the company was at $4.07 per share. Then on July 2nd, the company reached as high as $4.41 per share. Now on July 7th, NXE stock is at $4.17 per share on average. Considering these advancements, will you add NXE to your list of penny stocks?
NovaBay Pharmaceuticals Inc. (NYSE: NBY)
One biotech company performing well in the market right now is NovaBay Pharmaceuticals Inc. NovaBay is a medical device-focused company developing products for the eye care market. The company offers Avenova which is a solution for cleansing and removing foreign materials such as microorganisms and debris from the skin around the eye.
Its last update was back in May when it launched several new products to expand its Avenova line. The company launched its i-Chek Illuminated Eye Examination Mirror as a part of this expansion of the Avenova line.
President and CEO of NovaBay, Justin Hall said, “Those afflicted with bacterial dry eye can now examine their own eyes and view for themselves the buildup of scruff and debris on their lids and lashes before using Avenova. Then after applying our popular, soothing, and highly effective spray, they can visualize what they are feeling and the successful elimination of those conditions.”
While there is no clear news as to why shares of NBY stock are pushing up in recent sessions, it could be correlative momentum from the overall biotech sector. Whether this makes NovaBay Pharmaceuticals worth keeping an eye on is up to you.
9F Inc. (NASDAQ: JFU)
9F Inc. is a tech penny stock that we have mentioned several times in the past few months. This company operates a digital financial account platform integrating and personalizing financial services. The China-based company offers products such as digital financial accounts for online lending, wealth management, and more. It also has online wealth management products for stocks, insurance, banking, and more. The company’s platforms include Wukong Licai, 9F Wallet, and 9F Puhui.
9F Inc. has announced that it will hold an extraordinary general meeting on July 8th. The purpose of the meeting is for its shareholders to consider, and if thought fit, change the company’s name to ‘Ether Securities Inc.’. This is the latest update that has come from 9F Inc.
If we consider that JFU stock was at $1.13 per share when this year started we see a great deal of bullish interest in the company. Now JFU stock is sitting at around $2.37 per share as of July 7th. Considering this solid momentum, will JFU have a place on your penny stocks watchlist?
Arbutus Biopharma Corporation (NASDAQ: ABUS)
Another popular biotech penny stock is Arbutus Biopharma Corporation. ABUS is a pharmaceutical company that discovers, develops, and commercializes treatments and cures for patients with chronic Hepatitis B virus infection.
Its AB-729 product is a proprietary subcutaneously delivered RNA interference product candidate in a Phase IA/Ib clinical trial. This compound is targeted at hepatocytes and works to inhibit viral replication. Additionally, it can reduce various HBV antigens using novel covalently conjugated GalNAc delivery technology.
Arbutus received authorization to proceed with an Investigational New Drug Application for AB-729 on July 7th. The President and CEO said, “The acceptance of our IND application is an important step forward for AB-729 and supports our objective to establish its value as a cornerstone therapy for patients with CHB. We look forward to the initiation of this proof-of-concept Phase 2a clinical trial in this quarter.”
ABUS stock price has not had the best year overall in 2021. Despite this, the company has seen several bullish spikes throughout the past twelve months. If more developments are made by Arbutus, it could lead to more investor attention on the company. For now, however, will ABUS make your list of penny stocks to watch?
2 More Penny Stocks to Watch Right Now
Which Penny Stocks Are on Your Watchlist?
Creating a penny stocks-focused watchlist is not simple in 2021. But, with the right research and a commitment to education, it can be easier than previously imagined. If we consider the factors that are currently affecting both penny stocks and blue chips, we can begin to form a strategy for both short and long-term trading.
Additionally, investors should understand what type of trader they are, and use that to their advantage. Considering all of this, which penny stocks are on your list in 2021?